PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: LANXESS

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

LANXESS - Using Saltidin to Guard Against the Zika Virus - Insect repellents containing the active ingredient of Saltigo protect against infection with dangerous diseases by keeping mosquitoes at bay - /
LANXESS - Using Saltidin to Guard Against the Zika Virus


NewswireToday - /newswire/ - Leverkusen, Germany, 2016/02/02 - Insect repellents containing the active ingredient of Saltigo protect against infection with dangerous diseases by keeping mosquitoes at bay - / FRA: DE Frankfurt: LXS

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


People traveling a long way from home to tropical regions need to take particular care at the moment, because malaria and dengue fever are not the only diseases that can result from a mosquito bite in these warm and humid areas. In Latin America’s largest country Brazil, for example, the Zika virus is currently causing great concern and led the Brazilian authorities to declare a health emergency at the end of 2015. The World Health Organization (WHO) is not advising against travel to areas where the disease is endemic, but it is recommending keeping the insects that transmit the disease at bay by covering the skin with clothing, protecting beds with mosquito nets and using mosquito repellents, with icaridin a product of choice. Saltigo GmbH produces this tried-and-tested active ingredient and markets it under the brand name Saltidin. It is used by numerous manufacturers worldwide to formulate insect repellents. “Saltidin has already proved effective in preventing millions of people from being bitten by insects and we hope our active ingredient will make a key contribution to stemming the spread of the Zika virus,” said Saltigo Managing Director Wolfgang Schmitz.

The rapid spread of the virus is not restricted to the tropics. According to the latest reports, the Zika virus has also been found in blood samples of patients in the European countries of Italy, United Kingdom, Spain, Switzerland and Denmark. The patients in question had been infected while traveling overseas.

“Saltidin repels mosquitoes by acting on their odorant receptors, thereby disabling their ability to recognize humans as blood donors. Our active ingredient is neither an insecticide nor harmful to humans,” remarks Dirk Sandri, head of Marketing Fine Chemicals at Saltigo. This is a further major benefit of the product in addition to good compatibility with the skin, because it means that Saltidin-containing insect repellents can be utilized during pregnancy. It is particularly important at present to protect expectant mothers from being bitten by diurnal vector mosquitoes especially in Brazil, Colombia, Suriname, Samoa and Cape Verde because according to the Pan American Health Organization (PAHO), the rampant Zika virus is now suspected of causing malformations in unborn children in 18 Latin American countries and the Caribbean. Whether and how the virus causes microcephaly, as a result of which babies are born with abnormally small heads and mental retardation, remains to be clarified. Researchers are currently looking into the possible connection, but the results are only expected in a few months’ time.

The WHO declares a global emergency over the rapidly spreading Zika virus. The EU has been warning pregnant women not to travel to South America since November 2015 and the United States followed suit in mid-January. If such trips are essential, America’s CDC (Centers for Disease Control and Prevention) recommend insect repellents, including ones containing the active ingredient icaridin, for pregnant women, nursing mothers and children under the age of two.

The Zika virus originates from the Zika region of Uganda. Barely any research has been carried out on this virus, which was previously restricted to a small number of cases in Africa and isolated cases in Asia, and it is not yet entirely clear how it reached Brazil. What is certain is that, like dengue fever, the virus is transmitted by the Egyptian tiger mosquito, against which products based on Saltidin have proven effective. As with more familiar tropical infectious diseases, initial symptoms are seemingly harmless and include aching joints, a rash, headaches and a slight fever.

Saltidin provides versatile protection
In chemical terms, Saltidin is 1-(1-methylpropoxycarbonyl)-2-(-2-hydroxyethyl)piperidine, or icaridin for short. It has a neutral odor and does not irritate, sensitize or stick to the skin. The active ingredient is suitable for a very wide range of insect repellent formulations that are applied in a variety of ways. It is invisibly soluble in mixtures of alcohol and water, microbiologically stable, non-corrosive and compatible with a large number of plastics. Comprehensive laboratory and field testing proves its wide-ranging effectiveness against blood-sucking insects such as mosquitoes, flies, ticks, gnats, horseflies, ants and cockroaches.

Saltigo GmbH ( is a leading supplier in the field of custom synthesis. The company of specialty chemicals group LANXESS ( belongs to the Advanced Intermediates segment, which achieved total sales in 2014 of EUR 1,643 million. Saltigo, headquartered in Leverkusen and with production facilities in Leverkusen and Dormagen, employs around 1,200 staff worldwide.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: LANXESS


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

LANXESS - Using Saltidin to Guard Against the Zika Virus

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Zika Virus | Saltigo GmbH
Publisher Contact: Ilona Kawan - 
+49 221 8885 1684 ilona.kawan[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any LANXESS securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From LANXESS / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business




  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (